DelMar Pharma to initiate Phase III trial of VAL-083 to treat GBM

Canadian-based cancer therapies developer DelMar Pharmaceuticals is set to initiate a Phase III STAR-3 clinical trial of VAL-083 for the treatment of patients with refractory glioblastoma multiforme (GBM), following the approval from Institutional Re …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news